Single-use bioreactors (SUBs) are emerging as a key technology in the field of pharmaceuticals. Pharmaceutical and biopharmaceutical companies use single-use bioreactors for cell harvesting, purification, filtration, virus inactivation, and media and buffer preparation, among others. Single-use bioreactor can promote efficient ways for pharmaceutical companies to speed up and secure start-up and product development. Thus, single-use bioreactors have now become an integral part of biotechnology manufacturing facilities.
The global Single-Use Bioreactor Market is estimated to account for US$ 1,157.0 Mn in terms of value by the end of 2022.
Rise in use of single-use bioreactors by pharmaceutical and biopharmaceutical industry is expected to drive growth of the global single-use bioreactor market during the forecast period. For instance, SUBs have become an established addition to today’s biotechnology manufacturing facility. In December 2020, Thermo Fisher Scientific announced the launch of a single-use bioreactor (SUB) for cell culture production. The HyPerforma DynaDrive SUB delivers improved performance and scalability for larger volume cell culture processes. Moreover, the DynaDrive SUB offers superior scale and power compared to other solutions available, while also reducing capital investment and operational expenses due to reduced seed-train and scale-up processes.
Rise in demand for biologics across the globe is expected to offer significant growth opportunities for players in the global single-use bioreactor market. For instance, the increase in the development of biologics has increased the demand for SUBs. According to the data published in November 2021 by the U.S. Food and Drug Administration (FDA), Fact Sheet: FDA at a Glance’, there are 4,944 FDA-Registered Facilities for the development of biologics and around 6,799 for human drugs. Such a large number of manufacturing facilities for the production of biologics is expected to create opportunities for the use of single-use bioreactors.
High regular recurring expenses and regulatory concerns related to SUBs are factors expected to hinder growth of the global single-use bioreactor market. For instance, in most cases, SUBs are often made of plastic derivatives. Large-scale disposal of such plastic reactors is an environmental concern, and a major challenge, especially in countries where plastic disposal is strictly regulated. Moreover, SUBs incur more disposal costs compared to reusable units, and the cost involved in the waste management of large quantities of disposables is also high.
Global Single-Use Bioreactor Market - Impact of Coronavirus (Covid-19) Pandemic
The outbreak of COVID-19 pandemic had a significant impact on the single-use bioreactor market. SUBs are widely being used for the production of various COVID-19 vaccines. Bioreactors are used in cell culture-based viral vaccine production, especially during the COVID-19 pandemic. In 2020, Kemwell Biopharma upgraded its infrastructure to accelerate the development process. The expansion includes installation of Ambr 250, a high-performance equipment powered by 12 fully automated mini bioreactors at 250ml scale. Kemwell further expanded its manufacturing capacity with the addition of three new single-use bioreactors.
Moreover, Serum Institute of India had used single-use technology to accelerate supply of COVID-19 vaccine throughout India and other low- and middle-income countries.
To know the latest trends and insights prevalent in this market, click the link below:
The global single-use bioreactor market was valued at US$ 1,001.0 Mn in 2021 and is forecast to reach a value of US$ 2,768.3 Mn by 2028 at a CAGR of 15.6% between 2022 and 2028.
Among product type Single-use Bioreactor Systems segment held dominant position in the global single-use bioreactor market in 2021, accounting for 47.1% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Single-use bioreactors (SUBs) are emerging as a key technology and are being widely used in both pharmaceutical and biopharmaceutical companies. Single-use bioreactors enhance process safety and reduce the risk of cross contamination in highly potent biopharmaceutical ingredients with the extensive validation and qualification procedures. Thus, there is an increase in demand for SUBs, and this trend is expected to continue during the forecast period, driving the growth of the global single-use bioreactor market in the coming future.
Major players operating in the global single-use bioreactor market include
Sartorius AG, OmniBRx Biotechnologies, Merck KgaA, Solaris Biotechnology Srl, Eppendorf AG, Distek Inc., Celltainer Biotech BV, ABEC Inc., Thermo Fisher Scientific, and Danaher Corporation (Pall Corporation), among others.
In January 2020, Distek Inc. was awarded by the Prestigious IDEA Bronze Trophy for the BIOne 1250 Bioprocess Control System.
In September 2019, Merck completed the acquisition of Intermolecular Inc., a California-based company for advanced materials innovation.